摘要
目的:观察补肾化瘀生新方协同静脉溶栓治疗急性脑梗死的临床疗效及对脂蛋白相关磷脂酶A2 (lipoprotein-associated phospholipase A2,Lp-PLA2)、基质金属蛋白酶-9(matrix metalloprotei-nase-9,MMP-9)、超氧化物歧化酶(superoxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)的影响。方法:选择河南中医药大学第三附属医院脑病科2017年5月至2021年5月收治急性脑梗死患者83例,随机分为对照组41例和治疗组42例,对照组给予尿激酶静脉滴注治疗,溶栓后给予西药常规治疗,治疗组在对照组治疗的基础上口服补肾化瘀生新方,7 d为1个疗程。检测不同时间点血清中Lp-PLA2、MMP-9、SOD、MDA水平,Barthel指数评分,血管再通率及不良反应发生情况。结果:对照组有效率为87.80%,治疗组有效率为97.62%,两组有效率比较,差异有统计学意义(P<0.05)。对照组血管再通率为39.02%,治疗组为64.29%,两组血管再通率比较,差异有统计学意义(P<0.05)。两组患者治疗后24 h和7 d,Barthel指数评分高于治疗前,差异有统计学意义(P<0.05),且组间比较,差异有统计学意义(P<0.05)。对照组不良反应发生率为4.88%,治疗组为0%,两组不良反应发生率比较,差异有统计学意义(P<0.05)。两组患者治疗后24 h和7 d Lp-PLA2、MMP-9表达低于治疗前,差异有统计学意义(P<0.05),且组间比较,差异有统计学意义(P<0.05)。两组患者治疗后24 h和7 d MDA水平低于治疗前(P<0.05)、SOD高于治疗前(P<0.05),差异有统计学意义(P<0.05),且组间比较,差异有统计学意义(P<0.05)。结论:补肾化瘀生新方协同静脉溶栓可降低溶栓风险,提高临床疗效。
Objective:To observe the clinical curative effect of Formula for Nourishing the Kidney and Removing Blood Stasis and Generating the New combined with intravenous thrombolysis in the treatment of acute cerebral infarction and its influence on lipoprotein associated phospholipase A2(Lp-PLA2),matrix metalloproteinase-9(MMP-9),superoxide dismutase(SOD) and malondialdehyde(MDA).Methods:A total of 83 patients with acute cerebral infarction treated in the Department of Encephalology of Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from May 2017 to May 2021 were randomly divided into the control group with 41 cases and the treatment group with 42 cases.The control group was first treated with intravenous drip of urokinase and then routine treatment of Western medicine after thrombolysis.The treatment group was treated with Formula for Nourishing the Kidney and Removing Blood Stasis and Generating the New on the basis of the control group,and 7 days was regarded as a course of treatment.The levels of Lp-PLA2,MMP-9,SOD and MDA in serum,Barthel index score,vascular recanalization rate and adverse reactions were measured at different time points.Results:The effective rate was 87.80% in the control group and 97.62% in the treatment group.There was significant difference between the two groups(P<0.05).The recanalization rate of the control group was 39.02%,and that of the treatment group was 64.29%.There was significant difference between the two groups(P<0.05).The incidence of adverse reactions was 4.88% in the control group and 0% in the treatment group.There was significant difference between the two groups(P<0.05).The expressions of Lp-PLA2 and MMP-9 in the two groups were lower than those before treatment 24 hours and 7 days after treatment,and all the differences were statistically significant(P<0.05),and there were also statistical differences between the two groups(P<0.05).At 24 hours and 7 days after treatment,the level of MDA in the two groups was lower than that before treatment,while
作者
张俊
朱慧芳
王小雅
ZHANG Jun;ZHU Hui-fang;WANG Xiao-ya(Third Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou,Henan,China,450008;Henan University of Chinese Medicine,Zhengzhou,Henan,China,450046)
出处
《河南中医》
2022年第4期571-574,共4页
Henan Traditional Chinese Medicine
基金
河南省高校科技创新团队项目(17IRTSTHN024)。
关键词
急性脑梗死
补肾化瘀生新方
静脉溶栓
尿激酶
acute cerebral infarction
Formula for Nourishing the Kidney and Removing Blood Stasis and Generating the New
intravenous thrombolysis
urokinase
